Clinical Trial Update: A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC [Phase 2]

View source ↗

Summary

A Phase II study assesses AAA617 alone and in combination with an androgen receptor pathway inhibitor (ARPI) for PSMA PET scan-positive castration-resistant pro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• AAA617
• ARPI

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Prostatic Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING